DioTree is developing first-in-class small-molecule inhibitors of DIO3, a novel therapeutic target in high-grade serous carcinoma
OUR COMPANY
DioTree is a biotechnology company pioneering a new therapeutic approach to high-grade serous carcinoma (HGSC) through first-in-class small-molecule inhibition of DIO3. Our proprietary science has identified DIO3 as a druggable target in HGSC, forming the basis of a strategic drug-development program aimed at bringing a new targeted treatment approach to patients.
THE PROBLEM
High-grade serous carcinoma (HGSC) is an aggressive epithelial cancer involving the ovary, fallopian tube, and primary peritoneum, which are considered a single disease entity. Many HGSCs are thought to originate from secretory epithelial cells in the distal fallopian tube and progress through precursor lesions before spreading to the ovary and peritoneal surfaces.
Because early symptoms are often nonspecific and effective screening methods are lacking, most patients are diagnosed with advanced-stage disease. Treatment is based primarily on cytoreductive surgery and platinum-based chemotherapy, with maintenance and biomarker-directed therapies used when appropriate. Despite these advances, recurrence and treatment resistance remain common, emphasizing the need for new therapeutic approaches in HGSC.
